Two New Dilaudid Dosage Forms Are Available From Knoll

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 4 No 4
Volume 4
Issue 4

WHIPPANY, NJ--Two new forms of Dilaudid (hydromorphone HCL)-- Dilaudid 8 mg tablets and Dilaudid-5 Oral Liquid--are now available from Knoll Pharmaceutical Company.

WHIPPANY, NJ--Two new forms of Dilaudid (hydromorphone HCL)--Dilaudid 8 mg tablets and Dilaudid-5 Oral Liquid--are now availablefrom Knoll Pharmaceutical Company.

The 8 mg tablets allow easy titration to a higher hydromorphonedose and are more convenient for patients currently taking twoDilaudid 4 mg tablets per dose, the manufacturer said.

Dilaudid-5 Oral Liquid is designed for patients who have difficultyswallowing solid medications. One teaspoon contains 5 mg of hydromorphoneper 5 mL. The liquid is alcohol-free, colorless, unflavored, andcan be mixed with fruit juice, according to Knoll.

In addition, Knoll is making available a pocket guide "Strategiesfor Cancer Pain Management," written by Ada Rogers, RN, researchassociate and clinical coordinator of the Pain Research Group,Memorial Sloan-Kettering Cancer Center.

The guide contains general information on opioid use in cancerpain, as well as specific dosing information on Dilaudid, includinga dose conversion chart. Call 201-575-5656 (9 am to 5 pm EST)for free copies.

Related Videos
Samer A. Al'Hadidi, MD, with Rahul Gosain, MD, and Rohit Gosain, MD
Samer A. Al'Hadidi, MD, with Rahul Gosain, MD, and Rohit Gosain, MD
Samer A. Al'Hadidi, MD, with Rahul Gosain, MD, and Rohit Gosain, MD
Samer A. Al'Hadidi, MD, with Rahul Gosain, MD, and Rohit Gosain, MD
Samer A. Al'Hadidi, MD, with Rahul Gosain, MD, and Rohit Gosain, MD
video 8 - "Treatment Landscape for NSCLC With EGFR Exon 20 Insertion Mutations"
Video 7 - "Second-Line Treatment of Patients With EGFR-Mutated NSCLC"
A panel of 5 experts on liver cancer
A panel of 5 experts on liver cancer
A panel of 5 experts on liver cancer